Status:
COMPLETED
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
Lead Sponsor:
Tang-Du Hospital
Conditions:
Coronavirus Disease 2019 (COVID-19)
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.
Detailed Description
According to the results of nonclinical study of humanized Meplazumab for Injection, a single dose will be used for the treatment. The treatment plan is first dose on the first day (0d) and second dos...
Eligibility Criteria
Inclusion
- Men and women aged 18 to 75 years (inclusive)
- In line with the new coronavirus infection pneumonia diagnosis and treatment plan (trial version 4) issued by the Health Commission, patients with new coronavirus (2019 ncov) pneumonia were clinically diagnosed;
- The subjects must be able to understand the study and willing to participate in the study, and sign the informed consent (if the subjects with no behavioral ability think it is in their own interests to participate in the test, they should sign the informed consent by their legal guardian, or notify the consent by phone (recording) and explain it in the original medical record and other relevant documents).
Exclusion
- Known or expected to have allergic reactions or a history of allergy to any of the ingredients treated in this trial;
- In the judgment of the investigator, there are other reasons that the patient is not suitable to participate in this study.
Key Trial Info
Start Date :
February 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 9 2020
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04275245
Start Date
February 3 2020
End Date
March 9 2020
Last Update
April 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tangdu Hospital
Xi'an, Shaanxi, China, 710032